Uptrend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since May 5 · inside the Ichimoku cloud · RSI 41 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $646.0K | 0.00% | 28.65K | +140% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BDSX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 49.6 | 50.7 | -5.4 | -24.3 | 48.6 | 38.2 | -6.0 | 24.3 | 13.2 | -16.2 | +267.6% | ||
| 2025 | -32.7 | -23.0 | -21.2 | -14.6 | -43.4 | -6.6 | 24.8 | 21.3 | -11.6 | -9.5 | 21.2 | -17.9 | −77.8% |
| 2024 | 8.7 | -23.0 | -7.1 | -13.3 | 15.3 | 7.0 | 7.5 | 19.1 | -9.2 | -4.5 | -15.3 | 6.3 | −16.8% |
| 2023 | 4.3 | -14.2 | -9.7 | -7.0 | -19.1 | -12.1 | -3.3 | 31.9 | 5.1 | -13.9 | 4.9 | 23.5 | −20.0% |
| 2022 | -24.6 | -40.4 | -29.0 | -4.7 | -8.1 | 10.8 | 25.0 | -7.8 | -32.8 | -20.5 | 98.0 | 15.0 | −56.5% |
| 2021 | 19.9 | -18.4 | 2.9 | -19.4 | -11.7 | -8.6 | -28.9 | -3.9 | -8.9 | -8.3 | -9.5 | -22.4 | −73.8% |
| 2020 | 44.3 | 12.4 | +62.2% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | Schuler Jack WBeneficial Owner of more than 10% of a Class of Security | Purchase at price 24.47 per share. | 15K | $366.99K |
| Aug 10, 2026 | Schuler Jack WDivisional Officer | Purchase at price 24.01 - 24.25 per share. | 27.6K | $665.94K |
| Jun 29, 2026 | Patience JohnChairman of the Board | — | 1.4K | — |
| Mar 30, 2026 | Patience JohnChairman of the Board | — | 1.4K | — |
| Feb 22, 2026 | Hutton ScottChief Executive Officer | Sale at price 12.78 per share. | 1.5K | $19.04K |
| Feb 22, 2026 | O'Kane KieranOfficer | Sale at price 12.78 per share. | 535 | $6.83K |
| Feb 22, 2026 | Cowie Robin HarperChief Financial Officer | Sale at price 12.78 per share. | 535 | $6.83K |
| Feb 22, 2026 | Pestano Gary AnthonyOfficer | Sale at price 12.78 per share. | 556 | $7.10K |
| Feb 22, 2026 | Vazquez ChristopherOfficer | Sale at price 12.78 per share. | 211 | $2.70K |
| Feb 19, 2026 | Hutton ScottChief Executive Officer | — | 4.8K | — |
| Feb 19, 2026 | O'Kane KieranOfficer | — | 1.5K | — |
| Feb 19, 2026 | Cowie Robin HarperChief Financial Officer | — | 1.5K | — |
| Feb 19, 2026 | Pestano Gary AnthonyOfficer | — | 1.5K | — |
| Feb 19, 2026 | Vazquez ChristopherOfficer | — | 563 | — |
| Feb 9, 2026 | Hutton ScottChief Executive Officer | Sale at price 10.08 per share. | 3.6K | $35.89K |
| Feb 9, 2026 | O'Kane KieranOfficer | Sale at price 10.08 per share. | 584 | $5.89K |
| Feb 9, 2026 | Cowie Robin HarperChief Financial Officer | Sale at price 10.08 per share. | 941 | $9.49K |
| Feb 9, 2026 | Pestano Gary AnthonyOfficer | Sale at price 10.08 per share. | 540 | $5.45K |
| Feb 9, 2026 | Vazquez ChristopherOfficer | Sale at price 10.08 per share. | 101 | $1.02K |
| Feb 8, 2026 | Hutton ScottChief Executive Officer | — | 10K | — |
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Buy / hold / sell counts